COMP <GO>
TXG vs ABBV // REVENUE GROWTH (YOY)
10x Genomics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TXG 3
— ABBV 9
▲ REVENUE GROWTH (YOY) LEADER: ABBV
LAST: $70.11 (-14.03%) • MKT CAP: $10.63B
revenue-growth
5.20%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 70.20% | -1.10 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -5.70% | 29.00% | -34.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 3.47% | -2.25 | ABBV | /fcf-yield <GO> |
| Operating Margin | -9.50% | 24.60% | -34.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -6.80% | 6.90% | -13.70 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.20% | 8.60% | -3.40 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 25.02 | 5.33 | +19.69 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.5 | 72.8 | -28.29 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.15 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 113.1x | -89.10 | TXG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.63B | $513.86B | -$503.23B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | ABBV REV | TXG GROSS % | ABBV GROSS % | TXG FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $61.16B | 69.1% | 70.2% | $130.1M | $17.82B |
| FY 2024 | $610.8M | $56.33B | 67.9% | 70.0% | -$5.7M | $17.83B |
| FY 2023 | $618.7M | $54.32B | 44.0% | 44.0% | -$43.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
ABBV // BETA 1.15